PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26752952-10	2016	CONCLUSION: Our data show that TGF-beta1 serum levels decrease significantly at the EOT and remain decreased 6 months after the EOT mostly in chronic hepatitis C patients who achieve SVR after pegylated interferon-alpha and ribavirin combination treatment.	Ribavirin	224-233	transforming growth factor beta 1	Homo sapiens	31-40	
27215079-0	2016	Impact of TGF-beta1 Gene Polymorphism (rs1800469) on Treatment Response to Pegylated Interferon/Ribavirin in Iranian Patients with Hepatitis C. BACKGROUND: Hepatitis C virus as a major cause of chronic liver disease affects more than 170 million people worldwide.	Ribavirin	96-105	transforming growth factor beta 1	Homo sapiens	10-19	
16699498-5	2006	Combination therapy with interferon and ribavirin affects the tissue expression of TGF-beta-1 and NF-kappaB and favors metalloproteinase activity, and may thereby modulate hepatic fibrogenetic events.	Ribavirin	40-49	transforming growth factor beta 1	Homo sapiens	83-93	
24496160-12	2014	CONCLUSION: Overexpression of COX-2 and TGF-beta1 is an independent predictor for poor outcome of interferon and ribavirin therapy and these might be useful markers for the response to treatment.	Ribavirin	113-122	transforming growth factor beta 1	Homo sapiens	40-49	
16425392-0	2005	Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C. AIM: To evaluate the effect of antiviral treatment on plasma levels of transforming growth factor-beta1 (TGF-beta1), metalloproteinase 1 (MMP-1), and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with chronic hepatitis C. METHODS: TGF-beta1, MMP-1, and TIMP-1 plasma concentrations were measured by an enzyme immunoassay in 28 patients, during 48 wk of treatment with pegylated interferon-alpha 2b (PEG-IFN-alpha2b) plus ribavirin (RBV) and after 24 wk of follow-up.	Ribavirin	45-54	transforming growth factor beta 1	Homo sapiens	75-107	
15896245-3	2005	We undertook this study to simultaneously evaluate the effect of interferon alpha 2b plus ribavirin therapy on TGF-beta1 daily serum levels and on mRNA TGF-beta1 expression in liver biopsy specimens from 60 patients with chronic hepatitis C. METHODS: Serum levels of TGF-beta1 were measured by ELISA.	Ribavirin	90-99	transforming growth factor beta 1	Homo sapiens	111-120	
12145664-6	2002	In pegylated combination therapy with high dose ribavirin, lower levels of TNF-alpha, transforming growth factor beta (TGF-beta) and fibrosis scores were seen when comparing baseline with follow up.	Ribavirin	48-57	transforming growth factor beta 1	Homo sapiens	86-117	
12145664-6	2002	In pegylated combination therapy with high dose ribavirin, lower levels of TNF-alpha, transforming growth factor beta (TGF-beta) and fibrosis scores were seen when comparing baseline with follow up.	Ribavirin	48-57	transforming growth factor beta 1	Homo sapiens	119-127